%0 Journal Article %T HIV-Infection Reduction-Rates in Patients, on Antiretroviral Efficacy-Trial of a Nigerian Broad-Spectrum Antiviral Medicine (Antivirt<sup>&#174;</sup>) %A M. C. O. Ezeibe %A B. L. Salako %A F. I. O. Onyeachonam %A A. David %A O. O. Aina %A E. Herbertson %A M. E. Sanda %A I. J. Ogbonna %A E. Kalu %A N. U. Njoku %A M. I. Udobi %A C. A. Akpan %J World Journal of AIDS %P 141-148 %@ 2160-8822 %D 2020 %I Scientific Research Publishing %R 10.4236/wja.2020.102012 %X In verifying antiretroviral efficacy of a Nigerian broad spectrum antiviral medicine (Antivirt<sup>&#174;</sup>), the Nigerian Institute of Medical Research certified it safe by toxicological test on laboratory animals, before commencing treatment of three HIV/AIDS patients whose viral loads varied widely (millions, hundreds of thousands and thousands). To overcome errors associated with such wide differences in subject-classes, percentages of viral load-reductions were calculated instead of comparing their viral loads. After first month of the Antivirt<sup>&#174;</sup>-treatment, means of ranked viral loads of the patients significantly (P ¡Ü 0.05) increased from 10.00 ¡À 7.21 to 11.30 ¡À 5.51 (-41.03% infection-reduction rate) instead of reducing. From second month of the trial, their viral loads started to reduce, continuously, so that their infection-reduction rates have been increasing from that -41.03%, to -38.22% in the second month; 23.98% in the third month; 31.76% in the fourth month and 64.12% after the fifth month. %K Antivirt< %K sup> %K & %K #174 %K < %K /sup> %K Opposite Charges¡¯ Electrostatic Attraction %K Continuous Depletion Of HIV-Infection Loads %U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=101235